$AXGN

Began Marc A sold $3.2M of AXGN

Began Marc A (EVP & General Counsel) sold 67,500 shares of Axogen, Inc. (AXGN) at $47.34 ($3.20M total) on 2026-08-10 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Began Marc A
Published Aug 12, 2026, 8:13 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 12, 2026, 8:15 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$AXGN
Neutral
medium confidence
Mentioned
$AXGN
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$AXGNNeutralLow
01

Why it matters

This is a disclosed open-market sale by a senior officer under a pre-arranged 10b5-1 plan, with no accompanying company-specific catalyst in the text.

02

Market read

Traders may note the insider sale, but the pre-arranged nature and lack of new fundamentals make it a low-signal event.

03

What to watch

The article does not state whether the insider’s total holdings or future planned sales changed, nor does it provide context on compensation, taxes, or diversification needs.

Relevance 5/10Novelty 3/10Timing: filed 2026-08-12 after-hours; sale executed 2026-08-10

Background

The article is an SEC Form 4 insider transaction disclosure for Axogen, Inc.

Company-level read

Ticker impact

$AXGNNeutralMedium confidence
Context

Axogen disclosed an insider open-market sale by EVP and General Counsel Began Marc A of 67,500 shares at $47.3450 on 2026-08-10 under a 10b5-1 plan.

Expected impact

Low near-term impact; any reaction is likely muted and short-lived unless accompanied by other company-specific news.

Evidence & confidence

Form 4 details a pre-arranged 10b5-1 sale with no new operational, financial, or regulatory information disclosed in the text.

Market effects

No sector-level implications are provided; this is an issuer-specific insider transaction.

None indicated.

None indicated.

Counterpoint

Even with a 10b5-1 plan, repeated insider selling can still be interpreted by some traders as a sentiment check, potentially pressuring the stock if liquidity is thin.

Key entities

  • Axogen, Inc.

    US-listed company (AXGN) whose Form 4 insider sale is disclosed.

  • Began Marc A

    EVP and General Counsel who sold 67,500 shares under a 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$JNJMedAI 8/10

Weekly Buzz: JNJ Wins FDA Nod; AXGN, HCWB Strike Deals; ROIV, AZN, GPCR Lead Clinical Trials

Johnson & Johnson (JNJ) received CE Marking for ACUVUE OASYS MAX 2-Week contact lenses. GSK (GSK) expanded Shingrix approval in Japan. Axogen (AXGN) to acquire BioCircuit for $200M. Femasys (FEMY) partnered with CapexMD for fertility financing. EpilepsyGTx collaborated with Viralgen (BAYN.DE) for gene therapy. HCW Biologics (HCWB) partnered with Akron Biotech. Bluejay Diagnostics (BJDX) teamed with Lovell for federal market access. Transgene (TNG.PA) expanded partnership with ProBioGen. Oncolyti

$AXGNHighAI 9/10

Why is Axogen stock sliding today?

Axogen (AXGN) stock fell 9.0% in pre-market trading after announcing a $200M acquisition of BioCircuit Technologies and a $208.7M equity raise at a 10% discount. The deal includes a 30-day over-allotment option. Axogen expects the acquisition to boost revenue, EBITDA, and earnings. The stock drop is attributed to the discounted equity offering.

$AXGNHighAI 9/10

Axogen, Inc.: Axogen Enters into Definitive Agreement to Acquire BioCircuit Technologies

Axogen (AXGN) agreed to acquire BioCircuit Technologies for $200M, adding NerveTape, an FDA-approved sutureless nerve repair device. The deal is expected to boost revenue, EBITDA, and EPS while maintaining positive cash flow. Axogen plans to fund the acquisition with proceeds from a common stock offering. The transaction is set to close in Q4 2026, subject to conditions.

$ARGXMed

Here Are Wednesday’s Top Wall Street Analyst Research Calls: Atlassian, Dick’s Sporting Goods, EPAM Systems, GoDaddy, Intuit, Jersey Mike’s Subs, JFrog, Lattice Semiconductor, and More

Wall Street analysts issued upgrades, downgrades, and initiations for several companies. Upgrades include argenx (ARGX) to Buy at UBS, DT Midstream (DTM) to Outperform at Wolfe Research, and SolarEdge (SEDG) to Buy at UBS. Downgrades include Dick's Sporting Goods (DKS) to Hold at Truist, EPAM Systems (EPAM) to Neutral at JPMorgan, and Intuit (INTU) to Neutral at Bank of America. Initiations include Atlassian (TEAM) with Outperform at RBC, JFrog (FROG) with Outperform at RBC, and Lattice Semicond

$AXGNMedAI 8/10

Axogen (AXGN) Q2 2026 Earnings Call Transcript

Axogen (AXGN) reported Q2 2026 revenue of $69.7 million, up 23.1% year over year, driven by growth in breast, extremities, and OMF. Breast revenue grew more than 50% and contributed about two-thirds of growth. Gross margin was 72.7%. Adjusted net income was $7.3 million ($0.12/share). Full-year revenue guidance raised to at least $279 million (24% growth) and gross margin to at least 73%.

$AXGNMed

Axogen, Inc. (AXGN): Results of Operations and Financial Condition

Axogen, Inc. (AXGN) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Axogen, Inc. Reports Second Quarter 2026 Financial Results Raises Full Year Revenue Guidance to at Least 24% Growth or $279 million ALACHUA and TAMPA, FL – July 29, 2026 – Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical so